Frequently asked questions
Why is clinical research important?
Medical advances depend on participation of people in clinical studies, and every participant in a study makes a positive contribution towards learning more about medicine and future medical treatments, particularly for rare diseases where fewer patients are available to help. People who enter into clinical studies are contributing to the generation of data that may advance future treatments for the benefit of more patients.
How is a clinical study supervised?
Clinical research studies are regulated, following rules set by the United States Food and Drug Administration. The research study will follow a protocol, which is a detailed study plan explaining what researchers will do in the study.
Each research study must also be approved by an institutional review board (IRB). IRBs consist of groups of people who help protect the rights and welfare of people participating in research studies. IRBs are usually made up of doctors, scientists, religious representatives, and other medical and non-medical people.
Is there anything else I can do for my Fabry disease?
You do not have to be involved in this study to have treatment for your Fabry disease. Your other choices may include continuing your regular Fabry disease therapy, starting an approved therapy or taking part in a different study.
Can I leave the STAAR Study after it has begun?
Your participation in the study is voluntary – you can change your mind about being in the study at any time. You must tell the study doctor or study staff if you want to stop.
While you may decide to leave the study, please understand that the administration of a gene therapy is not reversible. For this reason, you may want to continue to be monitored for possible side effects and undergo health checks even after you decide to leave the study.
Will all study participants receive ST-920?
All patients who have passed the screening stage and enter into the STAAR Study will be assigned to receive the investigational gene therapy ST-920. However if there are unforeseen circumstances, such as stopping the study for safety reasons, then not all eligible patients may receive the study drug.
In addition, even if you have passed all of the screening tests, there is a possibility that you will not be enrolled in the study if the study has already recruited the required number of participants who meet all the inclusion requirements.
Do I need to stop my current treatments for Fabry?
No, you do not need to stop your ERT infusions. However, the study team will want to discuss the timing of your ERT infusions, as this has to be taken into consideration when scheduling your ST-920 infusion and blood samples.
If you are willing, and if it has been at least 4 weeks after your administration of ST-920, you may be able to withdraw from ERT administration. The study doctor will explain this in more detail when you next meet to discuss your potential participation in STAAR.
Stopping ERT is completely optional, and you do not have to stop ERT to participate in the study. However, you will not be able to take a chaperone therapy, like migalastat, during the STAAR clinical study.
How will my information be kept confidential?
Your privacy will be protected. We will keep your participation in this research study confidential to the extent permitted by law and will otherwise only disclose your private and personal information based on any permissions you grant to us.
The study doctor will discuss confidentiality with you in detail during the next stage of your discussions about the trial.
Will study participation cost me anything?
All study medication and study-related care will be at no cost to you. You could also receive reimbursement for travel.
Will I receive a payment if I join?
You will not be paid for being in this study.
How can I find out more about Fabry disease?
The following US patient groups provide information about Fabry disease: